Literature DB >> 32038753

Kaposi Sarcoma as a Cutaneous Vasculitis Mimic: Diagnosis and Treatment.

Sabeen Yaqub1,2, Shelly A Stepenaskie1,2, Fatemeh Jafari Farshami1,2, Wilmer L Sibbitt1,2, Monthida Fangtham1,2, N Suzanne Emil1,2, Arthur D Bankhurst1,2.   

Abstract

Painful, palpable purpura usually indicate underlying vasculitis. We report a case of systemic vasculitis treated with immunosuppression that developed painful, vasculitis-like purpuric lesions that progressed rapidly to fulminant Kaposi sarcoma (KS). These purpuric, tumorous lesions resolved completely following the suspension of immunosuppression; however, without immunosuppression, the underlying autoimmunity recurred. This case highlights the potential for early KS to present as a vasculitis mimic or pseudovasculitis that clinicians should keep in mind when purpuric, vasculitis-like lesions develop in an immunosuppressed patient with vasculitis. It is important to recognize these pseudovasculitis lesions as KS rather than recurrent vasculitis so that immunosuppression can be withdrawn.
Copyright © 2019. Matrix Medical Communications. All rights reserved.

Entities:  

Keywords:  Immunosuppression; Kaposi sarcoma; purpura; vasculitis

Year:  2019        PMID: 32038753      PMCID: PMC6937164     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  2 in total

Review 1.  Kaposi sarcoma in anti-neutrophil cytoplasmic antibody-associated vasculitis: a case-based review.

Authors:  Benedict K Tiong; Arun S Singh; G Peter Sarantopoulos; Tanaz A Kermani
Journal:  Rheumatol Int       Date:  2021-02-23       Impact factor: 2.631

2.  Evaluation of a training intervention to improve cancer care in Zimbabwe: Strategies to Improve Kaposi Sarcoma Outcomes (SIKO), a prospective community-based stepped-wedge cluster randomized trial.

Authors:  Katherine R Sabourin; Margaret Borok; Samantha Mawhinney; Maxwell Matimba; Francis Jaji; Suzanne Fiorillo; Dickson D Chifamba; Claudios Muserere; Busisiwe Mashiri; Chenjerai Bhodheni; Patricia Gambiza; Rachael Mandidewa; Mercia Mutimuri; Ivy Gudza; Matthew Mulvahill; Camille M Moore; Jean S Kutner; Eric A F Simões; Thomas B Campbell
Journal:  J Int AIDS Soc       Date:  2022-08       Impact factor: 6.707

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.